Menu Search
Equities

Dr Reddy's Laboratories Ltd

RDY:NYQ

Dr Reddy's Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)78.79
  • Today's Change-0.74 / -0.93%
  • Shares traded87.94k
  • 1 Year change+14.74%
  • Beta0.5544
Data delayed at least 15 minutes, as of Sep 19 2024 00:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy1
Outperform1
Hold1
Sell0
Strong Sell0

Share price forecast in INR

The 3 analysts offering 12 month price targets for Dr Reddy's Laboratories Ltd (ADR) have a median target of 87.22, with a high estimate of 92.23 and a low estimate of 78.35. The median estimate represents a 10.69% increase from the last price of 78.79.
High17.1%92.23
Med10.7%87.22
Low-0.6%78.35

Dividends in INR

In 2024, Dr Reddy's Laboratories Ltd reported a dividend of 40.23 INR, which represents a 29.38% increase over last year. The 20 analysts covering the company expect dividends of 39.56 INR for the upcoming fiscal year, a decrease of 1.67%.
Div growth (TTM)29.38%
More ▼

Earnings history & estimates in INR

On Jul 27, 2024, Dr Reddy's Laboratories Ltd (ADR) reported 1st quarter 2025 earnings of 83.46 per share. This result exceeded the 78.22 consensus of the 5 analysts covering the company and under-performed last year's 1st quarter results by 1.07%.
The next earnings announcement is expected on Nov 04, 2024.
Average growth rate-0.08%
Dr Reddy's Laboratories Ltd (ADR) reported annual 2024 earnings of 334.59 per share on May 07, 2024.
Average growth rate+22.63%
More ▼

Revenue history & estimates in INR

Dr Reddy's Laboratories Ltd (ADR) had 1st quarter 2025 revenues of 76.73bn. This bettered the 72.83bn consensus of the 14 analysts covering the company. This was 13.54% above the prior year's 1st quarter results.
Average growth rate+3.28%
Dr Reddy's Laboratories Ltd (ADR) had revenues for the full year 2024 of 280.11bn. This was 13.92% above the prior year's results.
Average growth rate+12.59%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.